Cutera Announces Expansion of FDA Indications for the truSculpt® Body Contouring System

CUTERA (Nasdaq:CUTR) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced the U.S. Food and Drug Administration (FDA) has granted clearance of an additional indication, for lipolysis or the breakdown of fat, on its premier non-surgical body sculpting system, truSculpt^® 3D.

As quoted in the press release:

“TruSculpt’s approval for lipolysis is exciting in two ways,” said Dr. Ashish Bhatia, Associate Professor of Clinical Dermatology at Northwestern University’s Feinberg School of Medicine.  “First, it confirms how this technology works to reduce areas of unwanted fat, and second, we know that lipolysis of fat cells leads to lasting results, which is great for our patients.”

“Today’s announcement is a major milestone for our Company and demonstrates our commitment in providing both our physician customers and patients one of the most effective body contouring solutions in the market today with clinically proven efficacy,” said James Reinstein, President and CEO of Cutera, Inc. “truSculpt 3D continues to demonstrate excellent market traction and is an important contributor to our planned revenue growth.  We will continue to develop technologies that advance the medical aesthetics industry and meet the needs of our customers and their patients.”

Click here to read the full press release.